IND application for ISTA

Article

ISTA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

ISTA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.

Bepotastine has three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor; it has a stabilizing effect on mast cells and it suppresses the migration of eosinophils into inflamed tissues. ISTA plan to initiate Phase II/III clinical trials in the US during the first quarter of 2007.

An oral formulation of bepotastine has been approved in Japan since July 2000 for the treatment of allergic rhinitis.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.